Characterization of human interferon stimulatory genes with antiviral potential against Ebola virus (360G-Wellcome-206959_Z_17_Z)
The understanding of the innate immune response to the highly pathogenic ebolavirus (EBOV) is currently limited. This project focuses on the IFN-stimulated gene SLC15a3 and its antiviral effect on EBOV in a recent unpublished screen by the host laboratory. The first main goal is to characterize how SLC15a3 inhibits EBOV replication using a safe replication-defective version of the virus by analyzing its effects on viral mRNA and genomic RNA production by qRT-PCR. Biochemically and fluorescently tagged versions of SLC15A3 will be analyzed by fluorescence microscopy to determine its localization within the cell and by using site directed mutagenesis to mutate the trafficking sequence of SLC15a3 to observe what effect this has on its antiviral properties. The second goal is to produce CRISPR/CAS9 SLC15a3 knockout cells and determine what effect the absence of SLC15a3 has on the sensitivity of the EBOV-like particles to type 1 IFN treatment. This project will lead to a greater understanding on how SLC15a3 effects the lifecycle of ebolavirus.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded |
0
|
| Applicant Surname | Digby |
| Approval Committee | Internal Decision Panel |
| Award Date | 2017-04-27T00:00:00+00:00 |
| Financial Year | 2016/17 |
| Grant Programme: Title | Vacation Scholarships |
| Internal ID | 206959/Z/17/Z |
| Lead Applicant | Miss Holly Digby |
| Partnership Value | 0 |
| Planned Dates: End Date | 2017-08-04T00:00:00+00:00 |
| Planned Dates: Start Date | 2017-06-05T00:00:00+00:00 |
| Recipient Org: Country | United Kingdom |
| Region | Greater London |